Pink Sheet Podcast: Affordability And The US Coronavirus Response, Biologics Transition Guidance May Force Strategy Changes
Pink Sheet reporter and editor consider congressional demands that government-funded coronavirus research produce affordable medicines and vaccines, as well as the one-word change to the biologics transition guidance that may affect the availability of authorized biosimilars.
You may also be interested in...
The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.
Trump and Biden trade barbs in debate that included a suggestion by the president that coronavirus vaccine development delays are political and saw Biden questioned on whether he was contributing to vaccine hesitancy.
Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.